OncoMatch/Clinical Trials/NCT06675214
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
Is NCT06675214 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Full course of PD-1/PD-L1 blockades and Cisplatin-based induction chemotherapy for nasopharyngeal carcinoma.
Treatment: Full course of PD-1/PD-L1 blockades · Cisplatin-based induction chemotherapy · Concurrent Chemotherapy — This prospective trial aims to enroll patients with stage III-IVA (AJCC 8th,) locoregionally advanced nasopharyngeal carcinoma (LANPC). Under the condition of full course of PD-1/PD-L1 blockades, patients who achieved radiological partial response after 3 cycles of platinum-based chemotherapy plus PD-1/PD-L1 blockades will be randomized in a 1:1 ratio to receive gradient radiotherapy (reducing the irradiation dose of PET-CT areas without metabolic abnormalities, while maintaining adequate irradiation dose of areas with metabolic abnormalities) or standard dose radiotherapy with concurrent chemotherapy. It is expected to provide a new therapeutic option for locally advanced nasopharyngeal carcinoma at moderate risk.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy plus immunotherapy — induction
after 3 cycles of induction therapy of platinum-based chemotherapy plus immunotherapy
Cannot have received: chemotherapy
Exception: except diagnostic treatment
prior chemotherapy, immunotherapy, targeted therapy, or surgery (except diagnostic treatment)
Cannot have received: immunotherapy
Exception: except diagnostic treatment
prior chemotherapy, immunotherapy, targeted therapy, or surgery (except diagnostic treatment)
Cannot have received: targeted therapy
Exception: except diagnostic treatment
prior chemotherapy, immunotherapy, targeted therapy, or surgery (except diagnostic treatment)
Cannot have received: surgery
Exception: except diagnostic treatment
prior chemotherapy, immunotherapy, targeted therapy, or surgery (except diagnostic treatment)
Cannot have received: anti-PD-1 therapy
Patients who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Cannot have received: anti-PD-L1 therapy
Patients who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Cannot have received: anti-CTLA-4 therapy
Patients who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Cannot have received: anti-angiogenic therapy
Patients who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Lab requirements
Blood counts
neutrocyte count0D40910e9/L, hemoglobin 0D90g/L, platelet count 0D1000910e9/L
Kidney function
creatinine clearance rate 0D 60 ml/min or creatinine of no more than 1.5 times the upper normal limit
Liver function
ALT/AST 2.50D ULN, bilirubin 2.50D ULN
Adequate marrow function: neutrocyte count0D40910e9/L, hemoglobin 0D90g/L and platelet count 0D1000910e9/L. Adequate liver and kidney function: ALT/AST 2.50D ULN, bilirubin 2.50D ULN.; creatinine clearance rate 0D 60 ml/min or creatinine of no more than 1.5 times the upper normal limit.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify